Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Citi
McKinsey
Cantor Fitzgerald
Queensland Health
UBS
Daiichi Sankyo
Cipla
Federal Trade Commission
Cerilliant

Generated: December 9, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR NATEGLINIDE

« Back to Dashboard

Clinical Trials for Nateglinide

Trial ID Title Status Sponsor Phase Summary
NCT00097786 Long-term Study of Nateglinide+Valsartan to Prevent or Delay Type II Diabetes Mellitus and Cardiovascular Complications Completed Novartis Pharmaceuticals Phase 3 This study is a test of the safety and effectiveness of two drugs, one for diabetes and one for hypertension, in keeping patients with high lab values of glucose from progressing to frank diabetes and developing cardiovascular complications. People in this study cannot have frank diabetes but are considered "borderline" based on blood tests. People in the study take none, one or both of the drugs and do not know which one(s) they are taking.
NCT00189774 Nateglinide: a Double Blind Add-on Study With Pioglitazone for Type 2 Diabetic Patients Completed Ajinomoto USA, INC. Phase 2/Phase 3 The purpose of this study is to investigate the superiority of nateglinide over placebo for inadequately controlled type 2 diabetic patients with pioglitazone treatment.
NCT00189774 Nateglinide: a Double Blind Add-on Study With Pioglitazone for Type 2 Diabetic Patients Completed Astellas Pharma Inc Phase 2/Phase 3 The purpose of this study is to investigate the superiority of nateglinide over placebo for inadequately controlled type 2 diabetic patients with pioglitazone treatment.
NCT00212290 Insulin Resistance and Central Nervous System (CNS) Function in Type 2 Diabetes Completed National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Phase 4 The purpose of this study is to examine the effects of treating insulin resistance on memory and attention, brain glucose utilization, and proteins in spinal fluid.
NCT00238472 A Pilot Study to Evaluate the Effects of Nateglinide vs. Glibenclamide on Renal Hemodynamics and Albumin Excretion Completed Novartis Pharmaceuticals Phase 4 This study is not being conducted in the United States. The purpose of the study is to evaluate the effects of nateglinide compared to glibenclamide on renal hemodynamics and albumin excretion.
NCT00259168 Insulin Resistance and Vessel Function After Meals: Does Early Intervention Make a Difference? Unknown status Bayer Phase 4 The purpose of this study is to determine whether attenuation/normalization of elevated blood sugar after meals ameliorates vessel wall (endothelial) function in individuals with insulin resistance.
NCT00259168 Insulin Resistance and Vessel Function After Meals: Does Early Intervention Make a Difference? Unknown status Novartis Phase 4 The purpose of this study is to determine whether attenuation/normalization of elevated blood sugar after meals ameliorates vessel wall (endothelial) function in individuals with insulin resistance.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Nateglinide

Condition Name

Condition Name for Nateglinide
Intervention Trials
Type 2 Diabetes Mellitus 7
Diabetes Mellitus, Type 2 6
Healthy 2
Insulin Resistance 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Nateglinide
Intervention Trials
Diabetes Mellitus 16
Diabetes Mellitus, Type 2 15
Insulin Resistance 2
Dyslipidemias 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Nateglinide

Trials by Country

Trials by Country for Nateglinide
Location Trials
Korea, Republic of 5
Japan 5
Canada 3
China 3
United States 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Nateglinide
Location Trials
Georgia 1
New Jersey 1
Washington 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Nateglinide

Clinical Trial Phase

Clinical Trial Phase for Nateglinide
Clinical Trial Phase Trials
Phase 4 13
Phase 3 3
Phase 2/Phase 3 1
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Nateglinide
Clinical Trial Phase Trials
Completed 19
Unknown status 2
Terminated 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Nateglinide

Sponsor Name

Sponsor Name for Nateglinide
Sponsor Trials
Novartis Pharmaceuticals 5
Drug Safety and Effectiveness Network, Canada 3
Canadian Institutes of Health Research (CIHR) 3
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Nateglinide
Sponsor Trials
Other 28
Industry 16
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Fuji
Chinese Patent Office
Julphar
Queensland Health
Accenture
Moodys
US Army
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.